On October 14, 2013 BioInvent reported that it has signed an extension to its 2008 license agreement with Bayer Pharma AG for the development of antibodies from BioInvent’s n-CoDeR libraries (Press release BioInvent, OCT 14, 2013, http://www.bioinvent.com/investors/press-releases/release.aspx?releaseid=817483 [SID:1234500560]). Under the terms of the extension, Bayer will broaden its access to BioInvent’s discovery and development technology platform.
BioInvent will receive an undisclosed license fee to cover new projects plus success-based milestone payments and royalties on products already in development.
The n-CoDeR libraries contain more than 20 billion (2 x 1010) highly diverse, fully human antibody fragments that have been created using BioInvent’s patented approach, generating antibodies with high affinity and selectivity.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!